Target Name: ZNF223
NCBI ID: G7766
Review Report on ZNF223 Target / Biomarker Content of Review Report on ZNF223 Target / Biomarker
ZNF223
Other Name(s): KRAB A domain | Zinc finger protein ZNF223 | Zinc finger protein 223 | zinc finger protein 223 | ZN223_HUMAN | Homo sapiens zinc finger protein 223

ZNF223: Key Regulator of Cell Proliferation and Pain Perception

ZNF223 (KRAB A domain) is a protein that is expressed in various tissues of the human body. It is a key regulator of cell proliferation and survival, and is involved in the development and maintenance of tissues such as the brain, heart, and gastrointestinal tract. ZNF223 has also been shown to play a role in the regulation of pain perception and neurodegenerative diseases.

The KRAB A domain is a unique structural feature that is found in many proteins, including ZNF223. It is a type of protein domain that is characterized by a specific sequence of amino acids that is conserved across different species. KRAB A domains are often found in proteins that are involved in signaling pathways, and they are thought to play a key role in the regulation of protein function.

One of the key functions of ZNF223 is its role in the regulation of cell proliferation. In cancer cells, the uncontrolled growth and division that occurs can lead to the formation of tumors. ZNF223 has been shown to play a role in the regulation of cell proliferation by controlling the activity of the oncogene transforming growth factor-beta (TGF-beta). This oncogene is responsible for promoting the growth and division of cells, and is a key factor in the development of many diseases, including cancer. By regulating the activity of TGF-beta, ZNF223 may be able to prevent the formation of cancerous tumors.

Another function of ZNF223 is its role in the regulation of pain perception. Pain is a highly unpleasant sensation that is often associated with injury or disease. The regulation of pain perception is an important function of the nervous system, and it is thought to be involved in the maintenance of physical and mental health. ZNF223 has been shown to play a role in the regulation of pain perception by controlling the activity of a protein called TrkA. TrkA is a G protein-coupled receptor that is involved in the sensation of pain, and its activity is regulated by ZNF223.

In addition to its functions in cell proliferation and pain perception, ZNF223 is also involved in the regulation of neurodegenerative diseases. neurodegenerative diseases are a group of conditions that are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. These conditions include Alzheimer's disease, Parkinson's disease, and Huntington's disease. ZNF223 has been shown to play a role in the regulation of neurodegenerative diseases by controlling the activity of a protein called Serpinepso. Serpinepso is a protein that is involved in the regulation of the breaking down of beta-amyloid peptides, which are thought to contribute to the development of neurodegenerative diseases.

Overall, ZNF223 is a protein that has important functions in the regulation of cell proliferation, pain perception, and neurodegenerative diseases. Its KRAB A domain, which is involved in the regulation of protein function, makes it an attractive target for drug development. Further research is needed to fully understand the role of ZNF223 in these processes, and to identify potential new treatments for a variety of diseases.

Protein Name: Zinc Finger Protein 223

Functions: May be involved in transcriptional regulation

The "ZNF223 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF223 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF224 | ZNF225 | ZNF225-AS1 | ZNF226 | ZNF227 | ZNF229 | ZNF23 | ZNF230 | ZNF232 | ZNF232-AS1 | ZNF233 | ZNF234 | ZNF235 | ZNF236 | ZNF236-DT | ZNF239 | ZNF24 | ZNF248 | ZNF25 | ZNF250 | ZNF251 | ZNF252P | ZNF252P-AS1 | ZNF253 | ZNF254 | ZNF256 | ZNF257 | ZNF26 | ZNF260 | ZNF263 | ZNF264 | ZNF266 | ZNF267 | ZNF268 | ZNF271P | ZNF273 | ZNF274 | ZNF275 | ZNF276 | ZNF277 | ZNF28 | ZNF280A | ZNF280B | ZNF280C | ZNF280D | ZNF281 | ZNF282 | ZNF283 | ZNF284 | ZNF285 | ZNF285CP | ZNF286A | ZNF286B | ZNF287 | ZNF292 | ZNF295-AS1 | ZNF296 | ZNF3 | ZNF30 | ZNF300 | ZNF300P1 | ZNF302 | ZNF304 | ZNF311 | ZNF316 | ZNF317 | ZNF318 | ZNF319 | ZNF32 | ZNF32-AS1 | ZNF32-AS2 | ZNF32-AS3 | ZNF320 | ZNF321P | ZNF322 | ZNF322P1 | ZNF324 | ZNF324B | ZNF326 | ZNF329 | ZNF330 | ZNF331 | ZNF333 | ZNF334 | ZNF335 | ZNF337 | ZNF33A | ZNF33B | ZNF33BP1 | ZNF34 | ZNF341 | ZNF341-AS1 | ZNF343 | ZNF345 | ZNF346 | ZNF347 | ZNF35 | ZNF350 | ZNF350-AS1 | ZNF354A